110 related articles for article (PubMed ID: 17761714)
1. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Boeck S; Wollenberg A; Heinemann V
Ann Oncol; 2007 Sep; 18(9):1582-3. PubMed ID: 17761714
[No Abstract] [Full Text] [Related]
2. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Brandi G; Venturi M; Dika E; Maibach H; Patrizi A; Biasco G
Cutan Ocul Toxicol; 2013 Oct; 32(4):336-8. PubMed ID: 23534992
[TBL] [Abstract][Full Text] [Related]
3. Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma.
Prejac J; Kekez D; Belev B; Kocić L; Bulimbašić S; Pleština S
Anticancer Drugs; 2020 Jan; 31(1):76-79. PubMed ID: 31567309
[TBL] [Abstract][Full Text] [Related]
4. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib.
Uchimiya H; Higashi Y; Kawai K; Kanekura T
J Dermatol; 2010 Jun; 37(6):562-4. PubMed ID: 20536674
[No Abstract] [Full Text] [Related]
5. Severe photosensitivity reaction to vandetanib.
Chang CH; Chang JW; Hui CY; Yang CH
J Clin Oncol; 2009 Sep; 27(27):e114-5. PubMed ID: 19564539
[No Abstract] [Full Text] [Related]
6. Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Macerelli M; Mazzer M; Foltran L; Cardellino GG; Aprile G
Tumori; 2015 Jul; 101(4):e122-7. PubMed ID: 25953445
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib.
Steins M; Thomas M; Geißler M
Recent Results Cancer Res; 2018; 211():1-17. PubMed ID: 30069756
[TBL] [Abstract][Full Text] [Related]
8. Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
Koutras AK; Mastronikolis NS; Evans TR; Papadeas ES; Makatsoris T; Kalofonos HP
Acta Oncol; 2008; 47(6):1171-3. PubMed ID: 18615326
[No Abstract] [Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
[TBL] [Abstract][Full Text] [Related]
11. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
12. Acute drug induced hepatitis due to erlotinib.
Ramanarayanan J; Scarpace SL
JOP; 2007 Jan; 8(1):39-43. PubMed ID: 17228132
[TBL] [Abstract][Full Text] [Related]
13. Atypical cutaneous vasculitis under lapatinib.
Peuvrel L; Quereux G; Brocard A; Saint-Jean M; Freour E; Josselin N; Audouin AF; El Kouri C; Dreno B
Eur J Dermatol; 2013; 23(4):540-1. PubMed ID: 23965414
[No Abstract] [Full Text] [Related]
14. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib: the first biologic in the management of pancreatic cancer.
Saif MW
Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
[TBL] [Abstract][Full Text] [Related]
18. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects.
Pomerantz RG; Chirinos RE; Falo LD; Geskin LJ
Arch Dermatol; 2008 Jul; 144(7):949-50. PubMed ID: 18645156
[No Abstract] [Full Text] [Related]
19. Long-term treatment of advanced hepatocellular carcinoma with the tyrosine kinase inhibitor erlotinib (Tarceva)--a case report.
Hass HG; Denzlinger C
Z Gastroenterol; 2009 Jan; 47(1):27-9. PubMed ID: 19156589
[TBL] [Abstract][Full Text] [Related]
20. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Riely GJ; Pao W
Cancer Biol Ther; 2005 Oct; 4(10):1096-7. PubMed ID: 16294020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
